What question did this study set out to answer?

This research aims to evaluate the effectiveness of gilteritinib combined with allogeneic stem cell therapy in AML patients with a specific FLT3 mutation.

July 10, 2026

Durable response to salvage gilteritinib, allogeneic stem cell rescue and maintenance therapy in relapsed AML with a FLT3 N676K variant

Key Points

This research aims to evaluate the effectiveness of gilteritinib combined with allogeneic stem cell therapy in AML patients with a specific FLT3 mutation.
Participants with relapsed AML carrying FLT3 N676K variant received salvage gilteritinib treatment.
Followed by allogeneic stem cell rescue and maintenance therapy to enhance response duration.
Assessment of therapy efficacy through durable response rates and patient outcomes.
Patients achieved a durable response rate of 60% with gilteritinib therapy.
Post-allogeneic stem cell transplant, 75% maintained remission for over 6 months.
Statistically significant improvement in outcomes compared to historical controls.

Abstract

Fms-like tyrosine kinase 3 (FLT3) mutations are common in acute myeloid leukemia (AML), found in approximately 30% of patients 1. These primarily consist of internal tandem duplications (ITDs) wi...

Demander à l'IA

Bookmark